Pharma, Biotech and Generics Industry News | The Pharmaletter
Dec 6, 2024 · Up to date news for the pharmaceutical and biotechnology industries - The Pharma Letter
Pharma and Biotech News | The Pharmaletter
Dec 30, 2024 · Japanese drugmaker Chugai Pharmaceuticals has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for Lunsumio (mosunetuzumab) for intravenous infusion 1mg and 30mg for the treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received two or more prior standard therapies.
Pharmaceutical Industry News | The Pharmaletter
Dec 2, 2024 · Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other.
Pharma and Biotech News in Brief | The Pharmaletter
Nov 22, 2024 · The US Food and Drug Administration (FDA) has issued the Federal Register notice, Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence, to encourage the submission of supplemental new drug applications to modify the labeling statements for buprenorphine-containing transmucosal …
week to August 30, 2024 - The Pharma Letter
Sep 1, 2024 · Regulatory news last week included European Commission approval for Swiss drugmaker Basilea’s antibacterial Cresemba, triggering a milestone payment from partner Pfizer. On the research front, Neurocrine Biosciences released mixed results from a Phase II study of its NBI-1117568 as a treatment for schizophrenia. Also, Alnylam Pharmaceuticals reported new …
Pharma and Biotech Insights | The Pharmaletter
Nov 11, 2024 · Pharma and Biotech News Insights. As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live.
Pharmaceutical Generics Industry News | The Pharmaletter
Medicines for Europe has launched a study of market barriers faced by European generics and biosimilar pharmaceutical companies operating in 11 key third-country markets.
2024: Emergent trends in pharma and biotech | Pharmaceutical
Dec 30, 2024 · The life sciences industry experienced volatility in 2024, marked by pipeline growth, biologics breakthroughs, and evolving GLP-1 therapies. Challenges in trials, manufacturing, and commercialization persisted, driving adoption of AI and innovative pricing models as the sector prepares for further innovation in 2025.
FDA drug regulation and approval news | The Pharmaletter
The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1), Sino-China biotech BeiGene.
Pharma Leaders | The Pharmaletter | The Pharmaletter
In recent years there has been an explosion of digital tools in the life sciences, but as with everything in pharma and biotech, their value hinges on the strength of the underlying data, making it essential to capture research in a robust way.